Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration

This publication has 33 references indexed in Scilit:

• Angiopoietin-2 Is Critical for Cytokine-Induced Vascular Leakage
  PLOS ONE, 2013
• Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
  Proceedings of the National Academy of Sciences, 2011
• Angiopoietin-1 Prevents VEGF-Induced Endothelial Permeability by Sequestering Src through mDia
  Developmental Cell, 2008
• Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
  New England Journal of Medicine, 2006
• Ranibizumab for Neovascular Age-Related Macular Degeneration
  New England Journal of Medicine, 2006
• Different effects of angiopoietin‐2 in different vascular beds in the eye: new vessels are most sensitive
  The FASEB Journal, 2005
• Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization
  Journal of Cellular Physiology, 2005
• Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood–retinal barrier
  Gene Therapy, 2004
• Angiopoietin-2 Is Required for Postnatal Angiogenesis and Lymphatic Patterning, and Only the Latter Role Is Rescued by Angiopoietin-1
  Developmental Cell, 2002
• Angiopoietin‐2 plays an important role in retinal angiogenesis
  Journal of Cellular Physiology, 2002